NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
முக்கிய அம்சங்கள்
Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.
SBIN Q3FY26 Results: Record Net Profit of ₹21,028 Cr, Up 24.5% YoY; Asset Quality Improves
State Bank of India (SBI) delivered a stellar performance in Q3FY26, reporting its highest-ever quarterly net profit of ₹21,028 crores, a 24.5% YoY increase. The bank's credit growth was robust at 15.1% YoY, significantly outpacing deposit growth of 9%, while maintaining a healthy domestic NIM of 3.12%. Asset quality reached multi-year highs with Gross NPA at 1.57% and a very low slippage ratio of 0.40%. With an ROE of 20.68% for the nine-month period, SBI continues to demonstrate strong operational efficiency and balance sheet strength.
முக்கிய அம்சங்கள்
Highest ever quarterly Net Profit of ₹21,028 crores, witnessing a growth of 24.49% YoY.Gross NPA ratio improved to 1.57% (down 50 bps YoY) and Net NPA ratio stands at 0.39%.Whole Bank Advances grew 15.14% YoY to ₹46.83 trillion, led by SME growth of 21.02%.Operating Profit for Q3FY26 surged by 39.54% YoY to ₹32,862 crores.Domestic Net Interest Margin (NIM) improved by 3 bps sequentially to 3.12%.
👀 கவனிக்க வேண்டியவை
The bank's record-breaking profit and exceptional asset quality metrics make it a strong performer in the PSU banking space. Investors should consider the stock for long-term portfolios given the robust credit demand and controlled credit costs.
Fitch Upgrades Biocon Biologics Outlook to Positive; Affirms 'BB-' Rating
Fitch Ratings has revised the outlook for Biocon Biologics from 'Stable' to 'Positive' while affirming its Long-Term Foreign-Currency Issuer Default Rating at 'BB-'. The upgrade reflects expectations of lower financial leverage after the company reduced liabilities using proceeds from a recent equity issuance. Additionally, the 'BB' rating on the subsidiary's USD 800 million secured notes was affirmed. This move signals improving creditworthiness and financial stability for the biosimilars business, which currently serves over 6.3 million patients globally.
முக்கிய அம்சங்கள்
Fitch Ratings revised Biocon Biologics' outlook to 'Positive' from 'Stable'Affirmed Long-Term Foreign-Currency Issuer Default Rating (IDR) at 'BB-'Affirmed 'BB' rating for USD 800 million secured notes issued by Biocon Biologics Global PlcOutlook improvement driven by sustained reduction in financial leverage via equity issuanceBiocon Biologics currently has 10 commercialized biosimilars and a pipeline of 20+ assets
👀 கவனிக்க வேண்டியவை
This rating upgrade indicates strengthening financial health and lower credit risk for the group's biosimilar arm. Investors should maintain a positive stance while monitoring the company's progress in debt reduction and biosimilar market expansion.
SBI Cards Shareholders Approve Appointment of Two Independent Directors for 3-Year Terms
SBI Cards and Payment Services Limited has received shareholder approval via postal ballot for the appointment of two Independent Directors. Smt. Anuradha Rao, former MD & CEO of SBI Funds Management, is appointed for a three-year term effective from November 13, 2025. Smt. Parvathy Vairava Sundaram, a former Executive Director at the Reserve Bank of India, is also appointed for a three-year term starting December 9, 2025. These appointments bring significant regulatory and strategic banking experience to the board, enhancing corporate governance.
முக்கிய அம்சங்கள்
Shareholders approved the appointment of Smt. Anuradha Rao as Independent Director for a 3-year term until November 12, 2028.Smt. Parvathy Vairava Sundaram's appointment as Independent Director approved for a 3-year term until December 8, 2028.Anuradha Rao brings nearly 40 years of experience, including roles as DMD at SBI and CEO of SBI Funds Management.Parvathy Vairava Sundaram is a former RBI Executive Director with expertise in Asset Quality Review and Risk Based Supervision.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for board-level oversight and governance. No immediate action is required as this is a routine but high-quality management update.
MobiKwik Achieves PAT Profitability in Q3 FY26; Payments GMV Hits Record ₹481 Billion
One MobiKwik Systems has successfully turned profitable in Q3 FY26, delivering a PAT of ₹4 crore and an EBITDA of ₹15 crore, marking a ₹59 crore YoY swing. The Payments business reached an all-time high GMV of ₹481 billion, supported by a 220% YoY growth in UPI transactions. Financial services saw a 126% YoY growth in ZIP EMI disbursals, reaching ₹900 crore for the quarter. Management has shifted to a risk-first lending approach, resulting in financial services gross profit jumping 405% YoY to ₹37.2 crore.
முக்கிய அம்சங்கள்
Achieved consolidated PAT of ₹4 crore and EBITDA of ₹15 crore (5% margin) for the first time.Payments GMV grew 63% YoY to ₹481 billion, with payments revenue reaching ₹223.7 crore.Personal loan disbursals hit ₹900 crore, with the ZIP EMI product growing 126% YoY.Consolidated contribution profit jumped 76% YoY to ₹128.8 crore due to margin expansion.UPI transactions grew 3.2x YoY, with the company maintaining an 18% market share in the wallet segment.
👀 கவனிக்க வேண்டியவை
Investors should view the turnaround to PAT profitability as a significant de-risking event for the company. Monitor the sustainability of the 17 bps payment margins and the credit quality of the lending book as they scale the 'risk-first' model.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rubicon Research Q3 FY26: PAT Surges 91% to ₹73 Cr; Revenue Up 52% on Strong US Demand
Rubicon Research reported a robust Q3 FY26 with revenue growing 52% YoY to ₹476 crores, driven by broad-based growth and market share gains in the US. Net profit (PAT) saw a significant jump of 91% to ₹73 crores, while EBITDA margins remained stable at 22.7% despite increased outsourcing costs to meet high demand. The company is on track to operationalize its Pithampur facility by mid-2026 to expand into high-potent oncology and hormones. With a healthy ROCE of 34% and a cash reserve of ₹334 crores, the company is well-positioned for future growth.
முக்கிய அம்சங்கள்
Revenue from operations grew 52% YoY to ₹476 crores in Q3 FY26, with 98% of revenue coming from the US.Profit After Tax (PAT) increased by 91% YoY to ₹73 crores with an EPS of ₹4.41 for the quarter.R&D investment stood at ₹52 crores (11% of revenue), which historically yields a 3.3x multiple in incremental sales.Pithampur facility commercialization is expected by Q1 CY2027 to handle excess demand currently being outsourced.Return on Capital Employed (ROCE) improved to 34%, reflecting high capital efficiency despite higher inventory levels for new launches.
👀 கவனிக்க வேண்டியவை
Investors should find confidence in the strong revenue ramp-up and stable EBITDA margins despite temporary gross margin pressure from outsourcing. The upcoming Pithampur facility and high ROCE suggest a sustainable long-term growth trajectory in the specialty pharma space.
Cantabil Retail Declares ₹0.75 Interim Dividend; Sets Feb 20 as Record Date
Cantabil Retail India Limited has announced an interim dividend of ₹0.75 per equity share for the financial year 2025-26. This payout represents 37.50% of the face value of ₹2 per share. The Board of Directors approved the distribution during their meeting on February 6, 2026. Shareholders must be on the company's records by February 20, 2026, to be eligible for the payment.
முக்கிய அம்சங்கள்
Interim dividend of ₹0.75 per equity share declared for FY 2025-26Dividend payout ratio stands at 37.50% of the ₹2 face valueRecord date for dividend eligibility is fixed as February 20, 2026Board meeting concluded at 12:55 PM on February 6, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the stock before the ex-dividend date to qualify for the ₹0.75 per share payout. Monitor the company's quarterly performance to assess the sustainability of such payouts.
Cantabil Q3 FY26 PAT Jumps 31% YoY to ₹45.1 Cr; Revenue Up 19%
Cantabil Retail reported a strong performance for Q3 FY26, with revenue growing 19% YoY to ₹264.4 crore and PAT increasing by 31% to ₹45.1 crore. The company expanded its footprint by adding 16 new stores during the quarter, bringing the total count to 646 across 317 cities. Operational metrics showed improvement with a 17.84% YoY volume growth and a healthy Same Store Sales Growth (SSG) of 5.85%. EBITDA margins also expanded significantly to 36.0% from 32.6% in the previous year's corresponding quarter.
முக்கிய அம்சங்கள்
Revenue from operations grew 19% YoY to ₹264.4 crore in Q3 FY26.Net Profit (PAT) increased by 31% YoY to ₹45.1 crore with a PAT margin of 17.1%.Added 16 new stores in Q3, reaching a total of 646 stores and 8.82 lakh sq. ft. retail area.Volume growth stood at 17.84% YoY, while Average Basket Value (ABV) rose to ₹4,949.EBITDA grew 31% YoY to ₹95.2 crore, reflecting strong operational efficiency and margin expansion.
👀 கவனிக்க வேண்டியவை
Investors should view the strong double-digit growth in both top-line and bottom-line as a positive sign of brand scaling and operational efficiency. The stock remains a watch for continued execution on its 'Vision 2027' expansion plans and maintenance of SSG above 5%.
OnMobile Q3 FY26 Revenue Up 4.5% QoQ to INR 1,369 Mn; Gaming Revenue Surges 27.5%
OnMobile reported a steady Q3 FY26 with revenue reaching INR 1,369 million, a 4.5% increase quarter-on-quarter. The mobile gaming segment was the standout performer, growing 27.5% QoQ to INR 453 million and now contributing one-third of total revenue. EBITDA grew 16% QoQ to INR 81 million, reflecting improved operational efficiency and cost discipline. The company also expanded its footprint by launching its gaming platform in Africa, supporting its long-term growth strategy.
முக்கிய அம்சங்கள்
Q3 FY26 revenue stood at INR 1,369 million, representing a 4.5% QoQ growthMobile Gaming revenue surged 27.5% QoQ to INR 453 million, with 13.7 million subscribersEBITDA increased to INR 81 million, up 16% QoQ excluding capitalizationMaintained a healthy gross cash balance of INR 1,385 million as of December 31, 2025Expanded global presence with a new gaming platform launch in Africa
👀 கவனிக்க வேண்டியவை
Investors should monitor the continued scaling of the high-margin gaming segment and the success of the new African expansion. The stock remains a play on the digital entertainment and mobile gaming turnaround.
OnMobile Appoints Former Comviva CEO Manoranjan Mohapatra as Independent Director for 5 Years
OnMobile Global has appointed Manoranjan Mohapatra as an Additional Independent Director for a five-year term effective February 5, 2026. Mr. Mohapatra is a seasoned industry veteran who served as CEO of Comviva Technologies for 17 years, where he led the company to 20x growth and expanded its footprint to 80 countries. His previous experience includes scaling Aricent Technologies to over $500 million in revenue as President and COO. This appointment brings significant strategic expertise in telecom, fintech, and digital transformation to the OnMobile board.
முக்கிய அம்சங்கள்
Appointment of Manoranjan Mohapatra as Independent Director for a 5-year term until February 2031Mr. Mohapatra previously led Comviva Technologies to 20x growth during his tenure as CEO from 2007 to 2024He scaled Aricent Technologies to revenues exceeding $500 million as President and COOBrings over 40 years of experience in building and scaling technology-led businesses in telecom and fintechThe appointment is subject to shareholder approval and follows a recommendation from the Nomination and Compensation Committee
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive governance move that adds high-caliber industry expertise to the board. Monitor how his strategic background in scaling digital businesses influences OnMobile's future growth initiatives.
OnMobile Q3 FY26 Results: Consolidated PAT at ₹35.13 Mn, Turnaround from YoY Loss
OnMobile Global reported a consolidated profit after tax (PAT) of ₹35.13 million for Q3 FY26, marking a significant recovery from a loss of ₹52.15 million in the same quarter previous year. Revenue from operations grew 5.9% sequentially to ₹1,356.90 million, although it remains lower than the ₹1,640.06 million reported in Q3 FY25. The company also announced the appointment of Manoranjan Mohapatra as an Independent Director to its board. An exceptional charge of ₹4.61 million was recognized during the quarter related to the implementation of new Indian Labour Codes.
முக்கிய அம்சங்கள்
Consolidated PAT turned positive at ₹35.13 million vs a loss of ₹52.15 million in Q3 FY25.Revenue from operations increased 5.9% QoQ to ₹1,356.90 million from ₹1,281.57 million.Total expenses reduced significantly to ₹1,407.97 million from ₹1,639.95 million in the year-ago period.Exceptional item of ₹4.61 million recorded due to the impact of new Labour Codes on gratuity.Appointment of Manoranjan Mohapatra as an Additional Independent Director to the Board.
👀 கவனிக்க வேண்டியவை
Investors should note the company's return to profitability and the sequential growth in revenue. The focus should remain on the sustainability of cost-cutting measures and the growth of the core mobile entertainment business.
Triveni Turbine Announces ₹2.25 Interim Dividend; Record Date Set for Feb 9, 2026
Triveni Turbine Limited has declared an interim dividend of ₹2.25 per equity share (face value ₹1) for the financial year 2025-26. The company has designated February 9, 2026, as the record date for determining eligible shareholders and as the cut-off for tax document submissions. Tax will be deducted at source (TDS) at 10% for resident shareholders with a valid PAN if the dividend exceeds ₹10,000, while a 20% rate applies for those without a PAN. Non-resident shareholders may benefit from lower tax treaty rates upon submission of required documentation like Form 10F and a Tax Residency Certificate.
முக்கிய அம்சங்கள்
Interim dividend of ₹2.25 per share declared for the financial year ending March 31, 2026.Record date for dividend entitlement and tax declaration submission is Monday, February 9, 2026.TDS of 10% applicable for resident individuals with PAN for dividend amounts exceeding ₹10,000.Non-resident shareholders can avail lower treaty rates by submitting electronic Form 10F and TRC.Dividend payments will be made exclusively through electronic modes as per latest SEBI mandates.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN, bank account, and email details are updated with their Depository Participant or RTA by February 9, 2026. Eligible investors should submit Form 15G/15H or other tax exemption documents via the Alankit portal before the record date to avoid higher TDS.
Panacea Biotec's Baddi Facility Receives GMP Non-Compliance From Hungary Regulator
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
முக்கிய அம்சங்கள்
NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.No quality risks were observed by regulators for products already released into the market.Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
👀 கவனிக்க வேண்டியவை
Investors should note that while the immediate revenue impact is negligible at 0.32%, the regulatory failure at a major facility is a sentiment negative. Monitor the timeline for CAPA implementation and successful re-inspection to ensure no broader compliance issues exist.
SBI Card Q3 FY26: PAT Jumps 45% YoY to ₹557 Cr; Spends Hit Record ₹1.15 Lakh Cr
SBI Card reported a strong 45% YoY growth in Profit After Tax (PAT) at ₹557 crore for Q3 FY26, driven by record spends and improved credit costs. Total spends reached an all-time high of ₹1,14,702 crore, marking a 33% YoY increase, while retail spends grew by 14%. Asset quality showed significant improvement with Gross Credit Cost declining to 8.3% and Stage 2 assets reducing by ₹246 crore sequentially. Despite a slight compression in NIMs to 11%, the company maintained a healthy ROA of 3.2% and ROE of 14.7%.
முக்கிய அம்சங்கள்
Profit After Tax surged 45% YoY to ₹557 crore, supported by lower credit costs and higher spend-based income.Total spends hit a record ₹1,14,702 crore (up 33% YoY), with online spends contributing 62.1% of retail volume.Gross Credit Cost improved to 8.3% from 9.0% in the previous quarter, reflecting better portfolio management.Cards-in-force grew 8% YoY to 2.18 crore, maintaining an 18.8% market share in the credit card industry.Management retained an additional provision of ₹121 crore despite an ECL-driven write-back opportunity to buffer against future volatility.
👀 கவனிக்க வேண்டியவை
Investors should view the improving asset quality and record spend levels as positive indicators of operational recovery. Monitor the growth in the EMI portfolio and the upcoming risk model refresh in Q4 for further margin stability.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.The new term is scheduled to run from April 1, 2026, through March 31, 2029.Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.The resolution requires approval as a Special Resolution via postal ballot.The cut-off date for shareholder eligibility was fixed as January 30, 2026.
👀 கவனிக்க வேண்டியவை
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
SBI Life Q3 FY26: AUM Crosses ₹5 Trillion, VNB Grows 17% to ₹50.4 Billion
SBI Life reported a strong performance for Q3 FY26, with Assets Under Management (AUM) crossing the significant ₹5 trillion milestone. The Value of New Business (VNB) grew 17% YoY to ₹50.4 billion, while VNB margins improved to 27.2% despite regulatory headwinds. Although reported Profit After Tax (PAT) grew by only 4% to ₹16.7 billion due to GST and labor law impacts, the adjusted profit growth stood at a robust 34%. The company continues to lead the private market with a 23.5% share in New Business Premium.
முக்கிய அம்சங்கள்
Assets Under Management (AUM) grew 16% YoY to reach ₹5.1 trillion.Value of New Business (VNB) increased by 17% to ₹50.4 billion with a margin of 27.2%.Individual Rated Premium (IRP) grew 15% to ₹166.8 billion, maintaining a 25.6% private market share.Indian Embedded Value (IEV) stood at ₹801.3 billion, representing an 18% YoY growth.Solvency ratio remains strong at 1.91, significantly above the regulatory requirement of 1.50.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's ability to maintain margins and market leadership despite regulatory changes. The strong growth in Embedded Value and AUM suggests long-term value creation potential.
Triveni Turbine Q3 FY26: Record Revenue of ₹6.24B, 225% Interim Dividend Declared
Triveni Turbine reported its highest-ever quarterly revenue of ₹6.24 billion, a 24% YoY increase, driven by a 54% surge in export sales. While EBITDA grew 16.9% to ₹1.54 billion, PAT remained stable at ₹917 million due to a one-time ₹157 million charge related to the new wage code. The company declared an interim dividend of ₹2.25 per share and maintains a healthy order book of ₹19.86 billion. However, quarterly order bookings saw a 26% YoY decline to ₹3.91 billion, primarily due to delays in export contract closures.
முக்கிய அம்சங்கள்
Highest ever quarterly Revenue of ₹6.24 billion (+24% YoY) and EBITDA of ₹1.54 billion (+16.9% YoY).Export sales grew significantly by 54% YoY, contributing 62% to the total quarterly revenue.Interim dividend of 225% (₹2.25 per share) approved for the financial year ending March 31, 2026.Total outstanding order book reached a record ₹19.86 billion, up 9% YoY, providing strong future visibility.Adjusted PAT (excluding exceptional items) grew 12.76% YoY to ₹1.04 billion.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong execution and record revenue, while monitoring the recovery in export order bookings which declined this quarter. The high dividend payout and robust order backlog suggest long-term stability despite short-term global trade uncertainties.
Triveni Turbine Q3 Revenue Up 32.5% YoY; Declares ₹2.25 Dividend and Re-appoints MD
Triveni Turbine reported a strong 32.5% YoY growth in standalone revenue from operations, reaching ₹5,840 million for the quarter ended December 31, 2025. The Board declared an interim dividend of ₹2.25 per share (225% of face value) with a record date of February 9, 2026. Net profit for the quarter was ₹952 million, impacted by a one-time exceptional expense of ₹157 million due to the New Labour Code. The company also ensured leadership continuity by re-appointing Mr. Nikhil Sawhney as Managing Director for a five-year term starting May 2026.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹5,840 million in Q3 FY26 from ₹4,406 million in Q3 FY25.Declared an interim dividend of ₹2.25 per equity share of face value ₹1 each.Profit before exceptional items and tax rose 27% YoY to ₹1,452 million.Recognized a one-time exceptional cost of ₹157 million related to employee benefit obligations under the New Labour Code.Re-appointed Mr. Nikhil Sawhney as Vice Chairman and Managing Director for 5 years effective May 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the strong top-line growth and management continuity as positive indicators of business health. The stock remains attractive for those seeking a mix of growth in the power equipment sector and consistent dividend yields.
Rubicon Research Approves Merger with KIA Health Tech and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, into the parent company to achieve operational synergies. KIA Health Tech, which was established for a manufacturing facility in Aurangabad, reported a net worth of ₹815.80 Lakhs and zero revenue as of March 2025. The company also strengthened its board by appointing Dr. Pradnya Saravade, a former IPS officer and SEBI investigation head, as an Independent Director. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
முக்கிய அம்சங்கள்
In-principle approval for merger with 100% subsidiary KIA Health Tech to drive operational synergies.Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs and net worth of ₹66,778.57 Lakhs for FY25.Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term starting February 2026.Resignation of Non-Executive Director Mr. Anand Agarwal, nominee of General Atlantic Singapore RR Pte Ltd.Appointment of M/s. BNP & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
👀 கவனிக்க வேண்டியவை
The merger of the wholly-owned subsidiary is a positive step toward corporate simplification and cost efficiency without equity dilution. Investors should also note the high-profile board appointment which enhances the company's governance and regulatory oversight profile.
Rubicon Research Q3 Net Profit Jumps 91% YoY to ₹728 Million; Revenue Up 52%
Rubicon Research reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 51.7% YoY to ₹4,755.29 million. Net profit surged by 91.2% YoY to ₹727.97 million, driven by robust operational growth despite a significant increase in R&D spending, which nearly doubled to ₹535.94 million. For the nine-month period, the company has already surpassed its full-year FY25 profit, reaching ₹1,699.50 million. Investors should note a post-quarter GST inspection mentioned in the auditor's report, though it has not yet impacted the financial results.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations rose 51.7% YoY to ₹4,755.29 million in Q3 FY26.Net Profit after tax saw a massive jump of 91.2% YoY, reaching ₹727.97 million.Research and Development (R&D) expenditure increased significantly to ₹535.94 million from ₹269.30 million YoY.Basic Earnings Per Share (EPS) improved to ₹4.46 in Q3 FY26 compared to ₹2.50 in the same quarter last year.Nine-month FY26 net profit of ₹1,699.50 million has already exceeded the full-year FY25 profit of ₹1,343.61 million.
👀 கவனிக்க வேண்டியவை
The company shows exceptional growth momentum and high R&D focus, making it a strong growth play in the pharma space. Investors should monitor the outcome of the GST inspection mentioned in the auditor's notes for any potential liabilities.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
